Blindness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The NMR structure of RD3 presented here provides a structural basis for elucidating RD3-RetGC interactions relevant for normal vision or blindness.
|
30559291 |
2019 |
Gonorrhea
|
0.010 |
Biomarker
|
disease |
BEFREE |
The 195-amino-acid-long human Retinal Degeneration Protein 3 (RD3) is critical in the regulation of guanylate cyclase (GC) signaling and photoreceptor cell survival.
|
29030614 |
2017 |
Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
However, the functional characterization of RD3 in tumor systems has been hampered by the dearth of information on its localization in normal tissue and by the lack of antibodies suitable for staining FFPE tissue, primarily due to the inaccessibility of the epitopes.
|
29030614 |
2017 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
While neuroblastoma is often RD3-positive, the adrenal medulla, where many neuroblastomas originate, is RD3-negative.
|
29030614 |
2017 |
Tumor Progression
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Recently, we identified significant loss of RD3 in high-risk neuroblastoma and the influential role of RD3 in tumor progression.
|
29030614 |
2017 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
While neuroblastoma is often RD3-positive, the adrenal medulla, where many neuroblastomas originate, is RD3-negative.
|
29030614 |
2017 |
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
While neuroblastoma is often RD3-positive, the adrenal medulla, where many neuroblastomas originate, is RD3-negative.
|
29030614 |
2017 |
High-Risk Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recently, we identified significant loss of RD3 in high-risk neuroblastoma and the influential role of RD3 in tumor progression.
|
29030614 |
2017 |
Retinal Diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
To explore potential association of the human RD3 gene at chromosome 1q32 with retinopathies, we performed a mutation screen of 881 probands from North America, India, and Europe.
|
17186464 |
2006 |
Retinitis Pigmentosa
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This enabled us to perform a mutational analysis of the C1orf36 coding region of about 300 patients affected by retinitis pigmentosa.
|
12914764 |
2003 |
Photoreceptor degeneration
|
0.020 |
Biomarker
|
disease |
BEFREE |
Deficiency of RD3 (retinal degeneration 3) protein causes recessive blindness and photoreceptor degeneration in humans and in the <i>rd3</i> mouse strain, but the disease mechanism is unclear.
|
31346032 |
2019 |
Amaurosis congenita of Leber, type 1
|
0.020 |
Biomarker
|
disease |
BEFREE |
Impaired association of retinal degeneration-3 with guanylate cyclase-1 and guanylate cyclase-activating protein-1 leads to leber congenital amaurosis-1.
|
25477517 |
2015 |
Photoreceptor degeneration
|
0.020 |
Biomarker
|
disease |
BEFREE |
This observation is consistent with the report of the role of RD3 in trafficking of GUCYs and gives further support to a common mechanism of photoreceptor degeneration in LCA12 and LCA1, i.e., inability to increase cytoplasmic cGMP concentration in outer segments and thus to recover the dark-state.
|
23308101 |
2013 |
Amaurosis congenita of Leber, type 1
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
RD3 (LCA12) was implicated as a LCA gene based on the identification of homozygous truncating mutations in two LCA families despite the screening of large cohorts of patients.
|
23308101 |
2013 |
Congenital cerebral hernia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Keratoconus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Muscle hypotonia
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Nystagmus
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Seizures
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Cataract
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Hemiplegia/hemiparesis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Electroretinogram abnormal
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Global developmental delay
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
hearing impairment
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Malformations of Cortical Development, Group II
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|